Methods |
For characteristics see ADVANCE 2011a2
|
Participants |
|
Interventions |
|
Outcomes |
|
Notes |
|
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not described |
Allocation concealment (selection bias) |
Unclear risk |
Not described |
Blinding of participants and personnel (performance bias) All outcomes |
Unclear risk |
Described as being double‐blinded but it was unclear how the blinding was performed |
Blinding of outcome assessment (detection bias) All outcomes |
Unclear risk |
Described as being double‐blinded but it was unclear how the blinding was performed |
Incomplete outcome data (attrition bias) All outcomes |
Low risk |
< 5% dropped out |
Selective reporting (reporting bias) |
Low risk |
All outcomes stated in the protocol were assessed |
Vested‐interest bias |
High risk |
The trial was funded by Bristol‐Myers Squibb |
Other bias |
Low risk |
The trial appeared to be free of other components that could put it at risk of bias |